# To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge

> **NCT00881673** · PHASE2 · WITHDRAWN · sponsor: **Alcon Research**

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** AL38583 Ophthalmic Solution
- **DRUG:** Maxidex
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT00881673
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-05
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Management decision
- **Last updated:** 2012-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00881673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00881673, "To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00881673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*